Granules India announced that its US step-down subsidiary, Granules Consumer Health, LLC, a wholly-owned subsidiary of Granules Pharmaceuticals, Inc., successfully completed a GMP inspection by the U.S. Food and Drug Administration (FDA) with zero observations. This was the facility`s second FDA inspection, following the March 2023 audit that resulted in a No Action Indicated (NAI) classification. Granules Consumer Health plays a critical role in our global operations as a packaging and distribution site. We process controlled substances and over-the-counter (OTC) products across three advanced packaging lines. Achieving zero observations in this inspection reflects our unwavering focus on quality, safety, and regulatory excellence, said Dr. Krishna Prasad Chigurupati, Chairman and Managing Director of Granules India. Granules Consumer Health serves as Granules` front-end division for OTC products in the U.S., leveraging Granules India`s manufacturing efficiencies, regulatory compliance, and integrated supply chain. Powered by Capital Market - Live News

Granules India inaugurated two advanced Centres of Excellence at the Technology Research Park of IIT Hyderabad: the Ascelis Center of Excellence for Peptide Development and Characterization and the Granules Center of Excellence for Particle Engineering.Ascelis Center of Excellence for Peptide Development and Characterization, established under Ascelis Peptides, the CDMO arm of Granules, this Centre will drive the development of cosmetic, therapeutic, and pharmaceutical peptides. It is Ascelis` first development and characterization facility in India and is equipped for primary, secondary, and tertiary structure characterization. The Center brings advanced analytical and process development capabilities in-house and will work in collaboration with our Swiss-based R&D facility Senn Chemicals, strengthening the group`s integrated global peptide offering and reducing reliance on external partners.Granules Center of Excellence for Particle Engineering, This Centre will advance polymorph research, material science, and novel drug delivery systems, including amorphous solid dispersions. It replaces earlier external and ad-hoc development with a dedicated research platform that enables first-to-file opportunities, enhances formulation performance, and supports the creation of proprietary technologies for regulated markets. Powered by Capital Market - Live News

Net profit of Granules India rose 34.33% to Rs 130.61 crore in the quarter ended September 2025 as against Rs 97.23 crore during the previous quarter ended September 2024. Sales rose 35.35% to Rs 1294.67 crore in the quarter ended September 2025 as against Rs 956.52 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales1294.67956.52 35 OPM %21.4921.26 - PBDT247.89180.91 37 PBT175.87128.38 37 NP130.6197.23 34 Powered by Capital Market - Live News

Net profit of Granules India rose 191.40% to Rs 120.61 crore in the quarter ended September 2025 as against Rs 41.39 crore during the previous quarter ended September 2024. Sales rose 57.26% to Rs 877.41 crore in the quarter ended September 2025 as against Rs 557.92 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales877.41557.92 57 OPM %24.0918.39 - PBDT202.6490.82 123 PBT161.9056.07 189 NP120.6141.39 191 Powered by Capital Market - Live News

Granules India today announced that its wholly owned subsidiary, Granules Life Sciences(GLS), located in Hyderabad (FEI: 3030495702), has received U.S. Food and Drug Administration (FDA) approval for a product that was the subject of a Pre Approval Inspection (PAI) conducted between 28 July and 01 August 2025.There was one observation during that inspection, and the GLS had submitted its response within the stipulated time.  With this approval, the GLS facility is now deemed approved by the U.S. FDA, marking a major milestone for Granules India as it expands its finished dosage manufacturing capabilities. This is the first FDA approval for the GLS site.The company plans to launch the approved product in the U.S. market soon. The same product is already approved and manufactured at Granules` Gagillapur facility. The new approval will help strengthen market share and support business continuity through multi-site manufacturing.Powered by Capital Market - Live News